Javed Butler, MD, discusses the overall results of the STEP-HFpEF trial, how he interprets the reduction in adjudicated heart failure events, and how the community's recent experience with SGLT2 inhibitors might inform uptake strategies for semaglutide 2.4 mg.
A secondary analysis of the DELIVER trial found dapagliflozin significantly reduced the full spectrum of worsening heart failure events, including outpatient oral diuretic intensification.
The largest trial to date, a meta-analysis, and new guideline recommendations have placed a spotlight on the role and benefit of iron supplementation in patients with heart failure and iron deficiency at ESC Congress 2023.
This new research highlights the advantages of patients with chronic spontaneous urticaria adhering to a daily maintenance non-sedating antihistamine schedule.
Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.
A study of 7 million-plus US adults shows telehealth visits for mental health conditions increased more than 10-fold during the COVID-19 pandemic.
This analysis on a larger study population led to results which add useful data to the growing literature on sesame thresholds and may even help to assess sesame safe doses used in risk management.
Patients receiving systemic corticosteroids faced an increased risk of severe COVID-19 requiring hospitalization or mechanical ventilation compared to other medication classes used to treat IBD.
This new data supports the use and feasibility of clinicians using longitudinal tobacco cessation care in the lung cancer screening setting.
Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.
A large systematic review assessing more than 60 drugs for bipolar depression shows only a handful were statistically signifcantly better than placebo per depressive symptom outcomes.
A proof-of-concept trial shows a program that addresses sleep pressure, circadian rhythm and hyperarousal in adolescents and young adults receiving mental health care is promising.
Disease activity improved by week 16 in patients receiving CT-P13 and was maintained through the end of the treatment period.
The FDA Circulatory System Devices Panel has voted in favor of the benefit-risk profile of Recor Medical's RDN system in a 10-2 vote but declined to endorse Medtronic's system in a 6-7 vote.
Presented at ESC 2023, the accumulation of inactive time from childhood through young adulthood was related to heart damage, regardless of body weight and blood pressure.
An analysis of data from more than 30,000 people with type 2 diabetes provides insight into the long-term use of metformin and risk of vitamin B12 deficiency.
The multi-center study led to several important findings, one of which being that history of biologic-use could be a factor of importance in secukinumab retention prediction.
Hypertension prevalence was significantly higher among adults with obesity and severe NAFLD, providing important information related to the association between hypertension and NAFLD severity.
When evaluating patient-education strategies among individuals with IBD, investigators found vaccine uptake was unaffected by educational videos and text-based interventions, identifying prior vaccine receipt as the strongest predictor of future vaccination.
This new data indicates that this not widely-practiced surgery for MCC, while effective, may first require initial implementation at higher-volume, regional centers for MCC due to existing infrastructure.
Across 31 centers in England, hybrid closed-loop therapy was associated with improvements in HbA1c, sensor glucometrics, and diabetes-related distress in adults with T1D.
A systematic review shows the muscle relaxant therapy is the lone intervention to benefit outcomes for the liver diseases among patients with alcohol use disorder, per randomized trials.
It is well known that glucocorticoids have adverse effects, but what specific adverse effects can patients with rheumatoid arthritis expect and what precautions should be taken with glucocorticoids to reduce the risk?
Apellis Pharmaceuticals identified internal structural variations in the 19-gauge filter needle included in certain injection kits for pegcetacoplan injection, the first FDA-approved treatment for geographic atrophy.
A pair of experts in the management of hypertrophic cardiomyopathy provide insight into the recent advances in management and reflect on what these advances have meant for patients.
These new results for tralokinumab could provide safer treatment options for older atopic dermatitis patients versus conventional therapies with greater risk of adverse events and drug-drug interactions.
Diagnostic survey results indicated 62.7% of participating patients with hepatitis C expressed a low level of satisfaction with life.
This new data is consistent with previous results on efficacy and on safety shown in global phase 3 studies that had enrolled both adults and adolescents.
A new analysis suggests improved self-recognition of myocardial infarction symptoms may reduce cardiogenic shock and death by prompting a rapid hospital visit.
